ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

ClinicalTrials.gov ID: NCT06635824

Public ClinicalTrials.gov record NCT06635824. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Study identification

NCT ID
NCT06635824
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Genmab
Industry
Enrollment
191 participants

Conditions and interventions

Interventions

  • Acasunlimab Drug
  • Docetaxel Drug
  • Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 24, 2024
Primary completion
Jul 29, 2027
Completion
Sep 29, 2028
Last update posted
May 4, 2026

2024 – 2028

United States locations

U.S. sites
36
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Arizona Blood and Cancer Specialists Tucson Arizona 85712
Usc Norris Comprehensive Cancer Center Los Angeles California 90089
Kaiser Permanente Vallejo Medical Center Vallejo California 94589
Ocala Oncology Center P.L. Ocala Florida 34474
Orlando Regional Medical Center Orlando Florida 32806
University Cancer & Blood Center, LLC Athens Georgia 30607
Piedmont Cancer Institute Atlanta Atlanta Georgia 30318
Piedmont Cancer Institute - Sandy Springs (Atlanta) Office Atlanta Georgia 30328
Piedmont Cancer Institute - Fayetteville Office Fayetteville Georgia 30214
Piedmont Cancer Institute - Newnan Office Newnan Georgia 30265
Piedmont Cancer Institute - Stockbridge Office Stockbridge Georgia 30281
Kaiser Foundation Hospitals Honolulu Hawaii 96817
University of Illinois Chicago Illinois 60612
Community Cancer Center East Medical Oncology Hematology Indianapolis Indiana 46219
Baptist Health Lexington Lexington Kentucky 40503
Norton Cancer Institute Louisville Kentucky 40202
Pikeville Medical Center Pikeville Kentucky 41501
Washington University School of Medicine St Louis Missouri 63110
St. Francis Hospital - Grand Island Grand Island Nebraska 68803
Oncology Hematology West Omaha Nebraska 68124
Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha Nebraska 68130
Stony Brook University Medical Center|University Medical Center Stony Brook New York 11790
Novant Health Pharmacy Charlotte North Carolina 28204
Novant Health Oncology Specialists Winston-Salem North Carolina 27103
University of Pennsylvania Health System Philadelphia Pennsylvania 19104
Allegheny General Hospital Pittsburgh Pennsylvania 15212
Avera Cancer Institute Sioux Falls South Dakota 57105
Parkridge Medical Center Chattanooga Tennessee 37404
University of Tennessee Medical Center Cancer Institute Knoxville Tennessee 37920
Midtown Tennessee Oncology Nashville Tennessee 37203
Tennessee Oncology Nashville Tennessee 37205
Texas Oncology-Austin Midtown Austin Texas 78705
Texas Oncology-Austin Central Austin Texas 78731
South Austin Cancer Ctr Austin Texas 78745
University of Virginia Hematology and Oncology Charlottesville Virginia 22903
Cancer Institute At Swedish Med Ctr Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 211 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06635824, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06635824 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →